NAD+ Precursors (AICAR/NIAM) for Energy Metabolism
The speaker advocates for subcutaneous administration of NAD+ boosters (referred to as 'AD plus' and likely AICAR/NIAM based on context) to refill the cellular energy tank. He explicitly states that oral versions are ineffective ('expensive piss') and must be injected to boost the core co-enzyme for energy metabolism and DNA repair.
NAD+ Stacking Compatibility
The speaker confirms that there are no known issues with stacking NAD+ supplements alongside Mots-c, describing NAD+ as a beneficial addition to the protocol.
Mitochondrial Peptides (NAD, Mots-c, SS-31) Deemed Unnecessary for Core Goals
The speaker explicitly states he does not use mitochondrial-targeted peptides including NAD, Mots-c, and SS-31, categorizing them as non-essential for his goals. He implies these compounds, while potentially legitimate, are not worth the cost for the average user pursuing body composition and general wellness. No mechanistic or clinical evidence is cited to support or refute their utility.
Cost-Saving Argument Against Complex Multi-Peptide Stacks
The speaker argues that consumers are wasting money by purchasing numerous peptides such as NAD, Mots-c, and SS-31, when a simple two-compound protocol can deliver equivalent or superior results. He claims this simplification can save 'thousands of dollars per month.' This is a cost-efficacy opinion with no comparative clinical or pharmacoeconomic data cited.
Dismissal of Mitochondrial Peptides (NAD, Mots-c, SS-31) as Unnecessary
The speaker explicitly states he does not use NAD, Mots-c ('Matzi'), or SS-31, categorizing them as mitochondrial peptides that are not necessary for his goals. He implies these compounds represent unnecessary spending for most users. This is a dismissal based on personal opinion and self-reported experience, not a controlled comparison.
Protocol Sourcing Recommendation: 503A Compounding Pharmacy for Peptide Procurement
The speaker recommends obtaining SS-31, MOTS-c, and NAD+ through a 503A compounding pharmacy (as opposed to research chemical websites) as part of a medically supervised protocol. He distinguishes between research site vials (accessible but unsupervised) and pharmacy-compounded peptides prescribed through a medical team, framing the latter as the safer and more effective approach due to proper sequencing guidance. No specific product names, concentrations, or dosages are mentioned.
NAD+ Is Technically a Co-Enzyme, Not a Peptide, But Grouped in Peptide Protocols
The speaker explicitly acknowledges that NAD+ is not technically a peptide but rather a co-enzyme, noting it is commonly grouped with peptides in the context of mitochondrial health and energy optimization protocols. This is a classification clarification rather than a mechanistic or clinical finding. No dosage information is provided.
Three-Peptide Mitochondrial Protocol: SS-31 → MOTS-c → NAD+ Sequential Stack
The speaker presents a specific three-compound sequential protocol for mitochondrial optimization: Step 1 — SS-31 to repair cristae structure and reduce ROS; Step 2 — MOTS-c to upregulate mitochondrial output and biogenesis; Step 3 — NAD+ to replenish the co-enzyme charge that powers the now-repaired and optimized system. He emphasizes that each layer enables the next and that running them out of order is the primary reason people fail to see results. No dosages, cycle lengths, or specific timing between phases are provided.
NAD+ May Be Used First as a 'Rescue' Intervention in Severely Depleted Patients
The speaker acknowledges an exception to the standard SS-31 → MOTS-c → NAD+ sequence: patients who are severely energy-depleted with brain fog and extreme fatigue may benefit from starting NAD+ early to achieve baseline functionality while the structural repair phase proceeds. He explicitly frames this as a 'rescue situation' rather than the optimal rebuild protocol, and recommends returning to the standard sequence when possible. No dosage is specified.
NAD+ Supplementation Is Inefficient When Mitochondrial Structure Is Compromised
The speaker argues that supplementing NAD+ before repairing mitochondrial structure is wasteful because the co-enzyme 'leaks out' of structurally damaged mitochondria rather than being utilized for energy production. He uses the analogy of charging a battery in a broken machine to illustrate why NAD+ should be the final step in the protocol. This is presented as a mechanistic rationale for sequencing, not based on a cited clinical study.
NAD+ Acts as the Primary Electron Carrier ('Charge') for Mitochondrial Energy Production
NAD+ is described as the essential co-enzyme that carries the electrochemical 'current' through the mitochondrial energy production process, and without sufficient NAD+ levels, the entire electron transport chain slows regardless of mitochondrial structural integrity. The speaker notes that NAD+ levels decline with age, contributing to the progressive dimming of cellular energy output even in otherwise healthy mitochondria. No specific dosage, form (NMN, NR, IV NAD+), or frequency is mentioned.
Peptides for Mitochondrial Health Should Be Sourced from Licensed 503A Compounding Pharmacies
The speaker distinguishes between research-site peptide vials (available without prescription) and pharmaceutical-grade peptides obtained through 503A compounding pharmacies under medical supervision. The speaker recommends the latter for patients pursuing this protocol, citing the importance of medical oversight for proper sequencing and quality assurance. This is presented as a safety and efficacy consideration rather than a regulatory warning.
Three-Compound Mitochondrial Protocol: SS-31 → MOTS-c → NAD+ Sequential Stack
The speaker presents a specific three-compound sequential protocol for mitochondrial optimization: (1) SS-31 first to repair inner mitochondrial membrane structure and reduce oxidative leakage, (2) MOTS-c second to activate mitochondrial biogenesis and increase output once the structural frame is sound, and (3) NAD+ third to replenish the co-enzyme substrate that fuels the now-repaired and optimized mitochondria. The speaker emphasizes that the order is non-negotiable for efficacy and that running them out of sequence is the primary cause of protocol failure. No specific dosages or cycle lengths are provided.
Early NAD+ Use as a 'Rescue' Exception for Severely Depleted Patients
The speaker carves out an exception to the standard SS-31 → MOTS-c → NAD+ sequence for patients who are severely symptomatic with brain fog, extreme fatigue, and functional impairment. In these cases, early NAD+ use is described as a 'rescue' measure to restore baseline functionality while structural repair proceeds. This is explicitly distinguished from the standard rebuild protocol and is not recommended as the default approach.
NAD+ Supplementation Is Largely Wasted When Used Before Mitochondrial Structural Repair
The speaker argues that administering NAD+ before repairing mitochondrial membrane integrity results in the co-enzyme being lost through the structural 'leaks' in dysfunctional mitochondria, analogized to charging a battery in a machine that cannot hold charge. This is presented as the primary reason NAD+ is recommended last in the three-compound protocol. The speaker acknowledges NAD+ is often the first compound people try due to its popularity.
NAD+ Levels Decline with Age, Contributing to Energy Reduction
The speaker states that NAD+ levels decrease as a function of aging, causing mitochondrial energy output to diminish even when the structural and biogenesis machinery is intact. This is analogized to a battery that no longer holds its charge. Replenishing NAD+ is presented as the third and final step in the mitochondrial optimization protocol, intended to sustain the gains made by SS-31 and MOTS-c.
NAD+ Acts as the Electron Carrier ('Charge') Required for Mitochondrial ATP Production
NAD+ is described as the essential co-enzyme that carries the electrochemical current through the mitochondrial electron transport chain, functioning as the 'charge' that powers ATP synthesis. The speaker notes that NAD+ is technically a co-enzyme rather than a peptide but groups it within this protocol. Age-related decline in NAD+ levels is cited as a key reason energy production diminishes over time even in otherwise functional mitochondria. No dosage is specified.
Mast Cell Density in Subcutaneous Fat as Mechanism for Peptide Allergic Reactions
Allergic reactions to subcutaneously injected peptides are attributed to mast cells, which have a greater density in subcutaneous fat compared to muscle tissue. The speaker characterizes these reactions as a 'false positive' triggered by mast cells. This mechanism is offered as the physiological explanation for why IM injections may reduce or eliminate allergic responses.
Intramuscular Injection as Alternative to Subcutaneous to Avoid Allergic Reactions
Intramuscular (IM) injection is presented as a viable alternative to subcutaneous (SubQ) injection for individuals experiencing allergic reactions to peptides. The speaker specifically names MOTS-c, NAD+, and Tesamorelin as peptides associated with these reactions. Switching to IM is stated to have no negative effect on peptide efficacy or the desired therapeutic outcome.
Mast Cell Density in Subcutaneous Fat as Mechanism for Peptide Injection Reactions
The speaker identifies mast cells as the primary mediators of allergic and anaphylactic reactions seen with subcutaneous peptide injections. These reactions are characterized as 'false positives,' implying the immune response is not a true pathological allergy to the peptide itself but rather a site-specific mast cell degranulation event. The higher density of mast cells in subcutaneous fat compared to muscle tissue is cited as the mechanistic explanation.
Intramuscular Injection as Alternative to Subcutaneous to Avoid Mast Cell Reactions
Injecting peptides intramuscularly (IM) rather than subcutaneously (SubQ) is presented as a viable strategy to avoid allergic reactions. The rationale is that mast cells — which are responsible for the false-positive allergic response — are present at greater density in subcutaneous fat tissue. Switching to IM delivery reduces exposure to this high-density mast cell environment. No dosage changes are mentioned; only the injection route changes.
Full Five-Tier Stacking Protocol — Complete Cellular Energy Stack Overview
The speaker outlines a comprehensive five-tier stacking protocol designed for cellular energy optimization. Tier one is foundational supplements; tier two adds NAD+ (50–100 mg SC, 3–5x/week); tier three adds Epitalon (500 mcg–1 mg/day, 10–20 days) and FOXO4-DRI (2–5 mg EOD, 3 doses); tier four adds SS-31 (2 mg/day SC) and MOTS-c (10 mg/week, MWF); tier five conditionally adds Five Amino 1MQ (50–100 mg/day), methylene blue (5–10 mg/day), and injectable L-carnitine (200–500 mg, 3–5x/week). All peptide tiers are cycled eight to twelve weeks on and four to eight weeks off.
Safety Framing — Lifestyle Foundation Is Non-Negotiable Before Peptide Use
The speaker issues a general safety and efficacy caveat that training, nutrition, and sleep must be established before any peptide or supplement protocol is layered on top. The explicit claim is that these protocols enhance existing work but cannot replace it. This functions as a contraindication-adjacent warning against using peptides as a substitute for foundational health behaviors.
Modular Protocol Design — Tiers Can Be Used Independently
The speaker explicitly frames the entire five-tier protocol as modular, meaning individuals do not need to implement all tiers simultaneously to observe results. Each tier is designed to build upon the previous, but partial adoption is presented as valid. This is a structural recommendation rather than a mechanistic or clinical claim.
Foundation-First Safety Principle: Lifestyle Before Peptides
The speaker issues a clear advisory that training, nutrition, and sleep are non-negotiable prerequisites before any peptide or supplement protocol is initiated. Peptides are framed as enhancers of existing healthy behaviors, not replacements for them. This is presented as a foundational safety and efficacy principle throughout the protocol.
Modular Protocol Design: Tiers Can Be Used Independently
The speaker explicitly frames the entire protocol as modular, meaning users do not need to implement all tiers simultaneously to see results. Each tier builds on the previous but can be used in isolation. This is presented as a practical safety and accessibility consideration rather than a clinical recommendation.
NAD+ Subcutaneous Injection Protocol for Cellular Energy Support
NAD+ is presented as a tier-two foundational intervention for feeding the cellular energy system. The recommended dose is 50–100 mg subcutaneous injection, administered three to five times per week. Cycling is emphasized: eight to twelve weeks on, followed by four to eight weeks off.